Colorectal cancer (CRC) patients, especially those with deficient mismatch repair
(dMMR)/microsatellite instability-high (MSI-H) tumors, whose sensitivity to immune …

Colorectal cancer (CRC) is highly heterogeneous at the genetic and molecular level, which
has major repercussions on the efficacy of immunotherapy. A small subset of CRCs exhibit …

Simple Summary Immune Checkpoint Inhibitors (ICIs) have demonstrated clinical efficacy in
Microsatellite Instability High Colorectal Cancer (MSI-H CRC). However, in Microsatellite …

Simple Summary The manuscript reports the most recent literature regarding treatment with
ICIs in mCRC, focusing on dMMR/MSI-H and POLE-mutated tumors, discussing current …

Background Mismatch repair (MMR)/microsatellite instability (MSI) and tumor mutational
burden (TMB) are independent biomarkers that complement each other for predicting …

Immune checkpoints inhibitors (ICIs) have been a breakthrough, with unique response and
survival patterns compared with chemotherapy for patients with advanced Mismatch Repair …

Following initial success in melanoma and lung tumours, immune checkpoint inhibitors
(ICIs) are now well recognized as a major immunotherapy treatment modality for multiple …

Background Immunotherapy with immune checkpoint inhibitors (ICIs) is highly effective in
microsatellite instability–high (MSI‐H) metastatic colorectal cancer (mCRC); however …

Colorectal cancer (CRC) is the third most common cancer type, and third highest in mortality
rates among cancer-related deaths in the United States. Originating from intestinal epithelial …

Background Microsatellite unstable colorectal cancers (MSI+ CRCs) expressing PD-L1,
respond to anti-PD-1 or anti-PD-L1 checkpoint blockade, whereas microsatellite-stable …